Debbie Rigby presents the latest in research news pertinent to pharmacy
The National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand have published new guidelines for the management of acute coronary syndromes or chest pain. Aspirin is recommended for all patients. For patients with confirmed ACS at intermediate to very high risk of recurrent ischaemic events, antiplatelet therapy is commended in addition to aspirin (dual antiplatelet therapy).
Med J Aust 2016; 205 (3): 128-133.
Findings from a systematic review and meta-analysis suggest that a Mediterranean diet with no restriction on fat intake may reduce the incidence of cardiovascular events, breast cancer, and type 2 diabetes mellitus but may not affect all-cause mortality.
Ann Intern Med. Published online 19 July 2016
A large UK population-based cohort study has concluded that GLP-1 analogues are associated with an increased risk of bile duct and gallbladder disease compared with current use of at least 2 oral antidiabetic drugs. There was no increased risk with DPP-4 inhibitors.
JAMA Intern Med. Published online August 01, 2016.
This Cochrane Review found that paracetamol does not produce better outcomes than placebo for people with acute low back pain, and it is uncertain if it has any effect on chronic low back pain. For acute low back pain, there is high-quality evidence for no difference between paracetamol (4 g per day) and placebo at 1 week (immediate term), 2 weeks, 4 weeks, and 12 weeks (short term) for the primary outcomes. Three trials were included in the review (n = 1825 participants), and two trials were included in the meta-analysis.
Cochrane Database of Systematic Reviews 2016, Issue 6.